Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099287 | 0.89 | JAK2 (0.31) | JAK2JAK1JAK3BRD4CREBBP | |
| SCHEMBL14697439 | 0.88 | PDE4B (0.35) | MAPTBRD4CREBBPDGAT1 | |
| SCHEMBL2105089 | 0.86 | JAK3 (0.42) | JAK2JAK1JAK3MAPTDGAT1 | |
| SCHEMBL10099305 | 0.85 | JAK2 (0.34) | JAK2JAK1JAK3MAPTBRD4 | |
| SCHEMBL566955 | 0.83 | SCN9A (0.38) | JAK2JAK1JAK3 | |
| SCHEMBL2105789 | 0.83 | PDE4B (0.46) | JAK2JAK1JAK3 | |
| SCHEMBL10099306 | 0.83 | MAPT (0.35) | JAK1JAK3MAPTBRD4CREBBP | |
| SCHEMBL10099303 | 0.81 | JAK2 (0.32) | JAK2JAK1JAK3MAPTBRD4 | |
| SCHEMBL10099185 | 0.80 | TSHR (0.37) | DGAT1 | |
| SCHEMBL10099184 | 0.78 | HTR6 (0.40) | JAK2JAK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.